Exhibit 99.1
ASX/Media Release
Immutep Announces Publication of Abstracts for ASCO 2023 Annual Meeting
| • | New data published from Part C of TACTI-002 Phase II Trial evaluating eftilagimod alpha plus pembrolizumab in metastatic 2nd line head and neck squamous cell carcinoma |
| • | Deep, durable responses seen across all PD-L1 subgroups with a 13.5% Complete Response rate and median Duration of Response not yet reached (minimum follow-up of 17 months) |
| • | In the overall patient population, regardless of PD-L1 expression, a strong response rate of 29.7% and 12-month overall survival rate of 46.0% were achieved |
| • | In patients with a PD-L1 Combined Positive Score of ≥20, a very promising response rate of 60% and 12-month overall survival rate of 66.7% were achieved |
| • | Treatment was safe and well tolerated with no new safety signals |
| • | More mature and final data will be presented during the poster session at ASCO 2023 |
SYDNEY, AUSTRALIA – 26 May 2023 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces data from Part C of its TACTI-002 Phase II trial has been published in an abstract available on the 2023 American Society of Clinical Oncology’s (ASCO) Annual Meeting’s official website. A Trial in Progress abstract for the Phase II/III AIPAC-003 trial has also been published.
The TACTI-002 poster will contain more mature (longer follow up) and final data that is not part of the abstract and will be available on the Posters & Publication section of Immutep’s website after its presentation at ASCO. Abstracts are available at ASCO.org.
TACTI-002 Abstract
Title: Final results from TACTI-002 Part C: A Phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with metastatic 2nd line head and neck squamous cell carcinoma unselected for PD-L1
Poster Session: Head and Neck Cancer
Date and Time: 5 June 2023, 2:15PM-5:15PM EDT
Presenter: Dr. Bernard Doger, START Madrid-FJD, Fundación Jiménez Díaz University Hospital, Madrid, Spain
Abstract #: 6029
AIPAC-003 Abstract
Title: AIPAC-003: A randomized, double-blind, placebo-controlled phase 3 trial testing eftilagimod alpha (soluble LAG-3) in HER2-neg/low metastatic breast cancer patients receiving paclitaxel, following an open-label dose optimization.
Poster Session: Breast Cancer – Local/Regional/Adjuvant
Date and Time: 4 June 2023, 9:00AM-12:00PM EDT
Presenter: Dr. Nuhad K. Ibrahim, Professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Abstract #: TPS1120
